Canadian women have their say on abortion options, access and knowledge More than 8 in 10 Canadian women strongly advocate for choice and access to abortion options 62% are concerned about their reproductive rights in Canada after the repeal of Roe v. Wade in the US 57% of Canadian women agree they know enough about […]
Author Archives: Dana
The reversal of Roe v. Wade in the US spearheaded conversations around abortion access and care in Canada. While Health Canada approved the abortion pill in 2015, restrictions around access especially access to safe abortion continued to exist in many parts of Canada, perhaps more visibly in Quebec until recently. Following the Supreme Court decision […]
This coming Thursday, June 6th, 2022, Linepharma General Manager, Marion Ulmann, will present data collected from the survey of 800 Quebec women in late 2021 at the Society of Obstetricians and Gynaecologists of Canada’s (SOGC) Annual Clinical and Scientific Conference (ACSC) in Quebec, Quebec. The survey was conducted by the national market research firm Leger. […]
LONDON and TOKYO, Dec. 22, 2021 /CNW/ – Linepharma International Ltd., a global leader in medical abortion, announced today that its subsidiary Linepharma KK has applied for manufacturing and marketing approval in Japan for its oral drug MEFEEGO™ for the medical termination of pregnancies of up to 63 days of gestation. The medication is recognized as the international gold standard for first […]
The Yomiuri Shimbun British pharmaceutical company Linepharma plans to apply to the Health, Labor and Welfare Ministry for approval of the abortion pill in late December, according to sources familiar with the matter. Approval is expected within a year if the review process goes smoothly. It would be the first orally consumed abortion pill, or […]
SURVEY SAYS……. Understanding therapeutic options is key when it comes to an abortion and Canadian women should be in the know as well as have equal access to those options. With that in mind we decided to find out what women had to say through a survey conducted by the national market research firm Leger. […]
Linepharma International, a leading provider of pharmaceuticals developed specifically for medication abortion, is pleased to announce it has received its pharmaceutical license in Japan on July 26, 2021. The pharmaceutical license is a crucial milestone for Linepharma International KK that is now allowed to register and distribute pharmaceutical products in Japan. This pharmaceutical license follows […]
Linepharma International Ltd. is pleased to announce that Mifeaprofa® (mifepristone 200mg) and Misoaprofa® (4 x 200µg misoprostol) have officially been launched in Chile via our local distribution partner Aprofa, part of The International Planned Parenthood Federation (IPPF) WHR. Mifepristone and misoprostol have been designated as an essential medicine by the World Health Organization (WHO) and has […]
Linepharma International is pleased to announce that mifepristone Linepharma 200mg has officially been launched in Bolivia as of the 27th of April via our local distribution partner Tecnologias en Salud S.A. (TES), part of The International Planned Parenthood Federation Western Hemisphere Region (IPPF WHR). Mifepristone has been designated as an essential medicine by the World […]
Linepharma International, a leading provider of pharmaceuticals developed specifically for medication abortion, is pleased to confirm its intention to bring medication abortion products to Japan. Following successful clinical trials that showed the combination of mifepristone and misoprostol to be successful in terminating a pregnancy in 120 abortion-seeking women between the ages of 18 and 45, […]